scispace - formally typeset
F

Fernando Pelaez

Researcher at Merck & Co.

Publications -  124
Citations -  7806

Fernando Pelaez is an academic researcher from Merck & Co.. The author has contributed to research in topics: Integrase & Farnesyl Protein Transferase. The author has an hindex of 41, co-authored 124 publications receiving 7350 citations. Previous affiliations of Fernando Pelaez include Autonomous University of Madrid.

Papers
More filters
Journal ArticleDOI

Discovery of natural product inhibitors of HIV-1 integrase at Merck

TL;DR: The evaluation of over 200,000 extracts originating from more than 50,000 microbial strains equally represented by fungi and actinomycetes led to the discovery of 24 novel classes of chemically diverse natural product inhibitors of HIV-1 integrase, representing a wide variety of classes with molecular weights ranging from 180-1,663 Da and HIV- 1 integrase-inhibitory activity IC 5 0 values ranging from 50 nM to > 100 μM.
Journal ArticleDOI

Presence of a simple tandem repeat in the ITS1 region of the Xylariales.

TL;DR: A Simple Tandem Repeat sequence of 11 nucleotides has been found in the ITS1 region of the rDNA of members of Order Xylariales, and it is shown that the presence of this sequence increases the normal rate of divergence in theITS1 of the Xylariaes.
Journal ArticleDOI

Molecular typing of Spanish species of Amanita by restriction analysis of the ITS region of the DNA

TL;DR: The genetic relatedness among 29 collections belonging to 20 of the most common species of genus Amanita in the Iberian Peninsula have been studied by means of restriction analysis of the amplified ITS1–5.8S-ITS2 region of rDNA, finding that this technique could be useful to identify and characterize isolates from Amanita species.
Journal ArticleDOI

Guanaconetins, new antitumoral acetogenins, mitochondrial complex I and tumor cell growth inhibitors.

TL;DR: Placement of acetyl groups along the alkyl chain modulated the potency of the bis-tetrahydrofuranic acetogenins and could be important for future utilization of these compounds as chemotherapeutic agents.